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Chondroitin sulfate (CS) anddermatan sulfate (DS) have been
implicated in the processes of neural development in the brain.
In this study, we characterized developmentally regulated brain
CS/DS chains using a single chain antibody, GD3G7, produced
by the phage display technique. Evaluation of the specificity of
GD3G7 toward various glycosaminoglycan preparations
showed that this antibody specifically reacted with squid CS-E
(rich in the GlcUA1–3GalNAc(4,6-O-sulfate) disaccharide
unit E), hagfish CS-H (rich in the IdoUA1–3GalNAc(4,6-O-
sulfate) unit iE), and shark skin DS (rich in both E and iE units).
In situ hybridization for the expression of N-acetylgalac-
tosamine-4-sulfate 6-O-sulfotransferase in the postnatal mouse
brain, which is involved in the biosynthesis of CS/DS-E, showed
a widespread expression of the transcript in the developing
brain except at postnatal day 7, where strong expression was
observed in the external granule cell layer in the cerebellum.
The expression switched from the external to internal granule
cell layer with development. Immunohistochemical localization
of GD3G7 in the mouse brain showed that the epitope was rela-
tively abundant in the cerebellum, hippocampus, and olfactory
bulb. GD3G7 suppressed the growth of neurites in embryonic
hippocampal neurons mediated by CS-E, suggesting that the
epitope is embedded in the neurite outgrowth-promotingmotif
of CS-E. In addition, a CS-E decasaccharide fraction was found
to be the critical minimal structure needed for recognition by
GD3G7. Four discrete decasaccharide epitopic sequences were
identified. The antibody GD3G7 has broad applications in
investigations of CS/DS chains during the central nervous sys-
tem’s development and under various pathological conditions.
Chondroitin sulfate (CS)3 and dermatan sulfate (DS) chains
are covalently linked to a wide range of core proteins, forming
proteoglycans (PGs)with awidespread distribution inmamma-
lian tissues (1). CS/DS-PGs are increasingly implicated as
important regulators of many biological processes, such as cell
proliferation and recognition (2, 3), cell adhesion andmigration
(4–6), neurite outgrowth (6, 7), and wound repair and anti-
coagulation processes (8–10). CS-PGs, which constitute the
major population of PGs in the central nervous system, influ-
ence the formation of neuronal nuclei and the establishment of
boundaries for axonal growth and act as modulators of neuro-
nal outgrowth (11). The CS chain’s backbone consists of repet-
itive disaccharide units containing D-glucuronic acid (GlcUA)
andN-acetylgalactosamine (GalNAc) residues, whereas DS is a
stereoisomeric variant of CS with varying proportions of L-idu-
ronic acid (IdoUA) in place of GlcUA. In mammalian tissues,
these chains are often found as CS/DS hybrid structures, and
further structural variability of these chains during chain elon-
gation is produced by divergent sulfation in the repeating dis-
accharide units by various sulfotransferases. Sulfation occurs at
C-2 of GlcUA/IdoUA and/or C-4 and/or C-6 of GalNAc in
various combinations, thereby producing characteristic sulfa-
tion patterns and enormous structural diversity. Recent studies
have shown that proportions of these disaccharide units in
chick, mouse, and pig brain change with development (12, 13),
suggesting that CS/DS chains differing in the degree and profile
of sulfation may be involved in the functional diversity of neu-
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rons during brain development.Moreover, oversulfated CS/DS
chains from various marine animals showed growth factor-
binding and neurite outgrowth-promoting activities in vitro
(14–17).
However, the reported functions of brain CS/DS chains in
neuritogenesis are controversial. CS/DS chains act as neurito-
genic molecules (for reviews, see Refs. 6, 18, and 19) and also as
inhibitors of axonal regeneration in the injured central nervous
system (20–23). Such apparently contradictory functions are
probably attributed to the structural diversity of CS/DS chains.
Significant and various proportions of disulfated disaccharide
units, such as the D unit (GlcUA(2S)-GalNAc(6S)) and E unit
(GlcUA-GalNAc(4S,6S)), are detected in the brain of cattle
(24), embryonic day 13 (E13)mice (25) and E18 rats (26) (where
2S, 4S, and 6S represent 2-O, 4-O, and 6-O sulfate groups,
respectively). Recently, we demonstrated that the rare oversul-
fated disaccharide units D and/or iD (IdoUA(2S)-GalNAc(6S))
and E present in embryonic pig brain-derived CS/DS chains are
critical elements for neuritogenesis (27). In addition, CS chains
from appican, the amyloid precursor protein expressed by rat
C6 glioma cells, contained significant proportions of D and E
units (28). CS-H, isolated from the hagfish notochord, has a
unique oversulfated structure characterized by a major disac-
charide H (or iE) unit (IdoUA-GalNAc(4S,6S)) (6, 18, 29, 30)
and therefore is actually DS. The term DS-E for this glycosam-
inoglycan (GAG) and iE (where “i” represents IdoUA) for the H
disaccharide unit have been proposed (6, 18). Further, exoge-
nous DS-E/CS-H exhibited appreciable inhibitory activity in
midkine (MK)-mediated neuronal cell adhesion similar toCS-E
(26). However, the presence of oversulfated CS-E and/or iE
structures in the mammalian brain has not been rigorously
characterized.
In biosynthesis, the structural variability of CS/DS chains is
generated under the control of multiple sulfotransferases and
glucuronyl C5-epimerase, which convertsGlcUA to IdoUA (for
reviews, see Refs. 31–33). Chondroitin 4-O-sulfotransferase-1
and -2 catalyze the 4-O-sulfation of GalNAc residues in chon-
droitin as well as in dermatan, whereas dermatan 4-O-sulfo-
transferase-1 catalyzes the 4-O-sulfation of GalNAc residues in
dermatan (Refs. 34–37). Several other sulfotransferases like
N-acetylgalactosamine-4-O-sulfotransferase-1 and -2, which
catalyze 4-O-sulfation at the nonreducing terminal GalNAc
residues in GalNAc1–4GlcNAc-, have also been cloned. On
the other hand, N-acetylgalactosamine-4-sulfate 6-O-sulfo-
transferase (GalNAc4S-6ST), which catalyzes the transfer of
sulfate to the 6-O-position of N-acetylgalactosamine-4-sulfate
(GalNAc4S), has been cloned (38) but not yet analyzed in the
brain. The gene expression pattern of this sulfotransferase
would provide clues for investigating the distribution of CS-E
chains in the brain.
Hence, we performed in situ hybridization to probe the dis-
tribution of GalNAc4S-6ST in postnatal mouse brain and also
studied the possible functions of E/iE-containing structures in
brain development using a new antibody, GD3G7, generated by
the phage display technique (39). Interestingly, a good correla-
tion between GalNAc4S-6ST expression and the GD3G7
epitope was observed in the mammalian brain.
EXPERIMENTAL PROCEDURES
Materials—The ScFv antibodyGD3G7was selected for reac-
tivity with rat embryo-derived GAGs by phage display as
described by ten Dam et al.4 DNA sequence analysis revealed
that antibody GD3G7 belongs to the Vh3 family, has a DP 38
germ line gene segment, and contains the heavy chain comple-
mentarily determining region 3 amino acid sequence
GRWTQMT. CS-A from whale cartilage, CS-B from porcine
skin, CS-C and CS-D from shark cartilage, CS-E from squid
cartilage, and chondroitinases ABC (EC 4.2.2.4), AC-I (EC
4.2.2.5), and B (EC 4.2.2) were purchased from Seikagaku Corp.
(Tokyo, Japan). CS-H from hagfish notochord was a gift from
the late Prof. Nobuko Seno (Ochanomizu University, Tokyo,
Japan), and DS from shark skin was prepared as described ear-
lier (17). Postnatal day 7 (P7), P14, P21, 7-week-old male and
pregnant ddY mice were purchased from SLC Inc. (Shizuoka,
Japan). The monoclonal anti-VSV tag antibody P5D4 and
porcine intestinal mucosal heparin were obtained from
Sigma, and alkaline phosphatase-linked goat anti-mouse Ig
(G  M) was purchased from StressGen Biotechnol Corp. (San
Diego, CA). A SuperdexTM Peptide HR 10/30 column was
obtained fromGEHealthcare Bio-Sciences (Tokyo, Japan). EZ-
LinkTM biotin-LC-hydrazide was obtained from Pierce. Even-
numbered, saturated oligosaccharide (tetra- to hexadecasac-
charide) fractions were prepared by the partial enzymatic
digestion of a commercial CS-E from squid cartilage with sheep
testicular hyaluronidase as described previously (40), and struc-
turally defined CS-E octa- and decasaccharides were prepared
as described by Deepa et al. (41). Poly-DL-ornithine and anti-
neurofilament antibody were purchased from Sigma, and
MAP2 (anti-microtubule-associated protein 2) was from Leico
Technologies Inc. (St. Louis, MO). Laminin isolated from
Engelbreth-Holm-Swarmmouse tumorwas from Invitrogen. A
Vectastain ABC kit was obtained from Vector Laboratories.
35S-Labeled 3-phosphoadenosine 5-phosphosulfate (PAPS)
was purchased from PerkinElmer Life Sciences.
Enzyme-linked Immunosorbent Assay (ELISA)—For the eval-
uation of the specificity of the antibody in antigen recognition,
streptavidin-coated plates were used. The reactivity of the anti-
body with various GAG subtypes was tested by ELISA as
described previously (42). Briefly, the GAGs were individually
biotinylated and immobilized on the plates.Wells were blocked
with 1% bovine serum albumin (BSA) and incubated with
10-fold diluted primary antibody GD3G7. Since this antibody
contains a VSV tag, the tag was used to detect binding of the
antibody. A hybridoma supernatant of the anti-VSV tag mouse
monoclonal antibody P5D4 in 0.1% BSA, phosphate-buffered
saline (PBS) (diluted 5,000-fold) was used, followed by alkaline
phosphatase-linked goat anti-mouse Ig (G  M). Enzymatic
activity was detected using p-nitrophenylphosphate, and the
absorbance was measured at 415 nm.
For the inhibitory ELISA, a certain amount of GAG, even-
numbered oligosaccharide, or structurally defined oligosaccha-
ridewas incubatedwith the antibodyGD3G7 (periplasmic frac-
4 G. B. ten Dam, E. M. A. van de Westerlo, A. Purushothaman, H. Bulten,
F. C. G. J. Sweep, L. Massuger, K. Sugahara, and T. H. van Kuppevelt, submit-
ted for publication.
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tion, diluted 10-fold) in a total volume of 50 l at room
temperature for 1 h before being applied to CS-E and strepta-
vidin-coated plates. The inhibition was calculated from the
reduced absorbance relative to that obtained from a control
incubation without GAG.
Construction of a Soluble Form of GalNAc4S-6ST—A
zebrafish GalNAc4S-6ST was identified in silico by a
TBLASTN search using as a query sequence the mouse coun-
terpart (GenBankTMaccessionnumberAB187269). The cDNA
encoding a truncated form of zebrafish GalNAc4S-6ST lacking
the first NH2-terminal 81 amino acid residues was amplified by
PCR with the pGEM-T Easy Vector containing the full coding
sequence of the protein using a 5-primer containing an in-
frame BamHI site (5-GCGGATCCGGGCTCTTTTTAA-
CACC-3) and a 3-primer containing a BamHI site located 77
bp downstream from the stop codon (5-GCGGATCCAC-
CAAGCATCGGCCT-3). PCR was carried out with KOD-
plus-DNA polymerase (TOYOBO, Tokyo) by 30 cycles at 94 °C
for 30 s, 59 °C for 42 s, and 68 °C for 90 s. The PCR products of
the expected sizewere digestedwithBamHI and cloned into the
BamHI site of an expression vector, pEF-BOS/IP (43). The
resultant vector contained the insulin leader peptide and a pro-
tein A IgG-binding domain followed by the truncated form of
zebrafish GalNAc4S-6ST.
Expression of a Soluble Form of Putative GalNAc4S-6ST and
Enzyme Assay—The expression plasmid was introduced into
COS-1 cells in 100-mm plates using FuGENETM 6 (Roche
Applied Science) according to the manufacturer’s instructions.
Two days after the transfection, a 1-ml aliquot of the culture
medium was incubated with 10 l of IgG-Sepharose beads (GE
Healthcare Bio-Sciences) for 1 h at 4 °C. The enzyme-bound
beads were washed with and resuspended in the assay buffer
described below and used as an enzyme source for the sulfo-
transferase assay.
Sulfotransferase activity toward CS/DS was assayed by a
method described previously (44). Briefly, the standard reac-
tion mixture (60 l) contained 10 l of the resuspended beads,
50 mM imidazole-HCl, pH 6.8, 2 mM dithiothreitol, 10 M
[35S]PAPS (1 or 3  105 dpm), and CS-B from porcine skin,
which had been pretreated with nitrous acid as the acceptor
polysaccharide (2 g as GlcUA). The reaction mixture was
incubated at 37 °C for 1 h and subjected to gel filtration using a
syringe column packed with Sephadex G-25 (superfine) (45).
The incorporation of [35S]sulfate into the polysaccharide
acceptorwas quantified by determination of the radioactivity in
the flow-through fractions by liquid scintillation counting.
Identification of the Transferase Reaction Products—The 35S-
labeled CS-B was isolated by gel filtration as described above,
dried, and subjected to exhaustive digestion with chondroiti-
nase ABC, AC-I, or B (46). The digest was analyzed by anion
exchange HPLC on a column of amine-bound silica PA03 (47)
or by gel filtration on a column of SuperdexTM peptide (GE
Healthcare Bio-Sciences) equilibrated with 0.2 M NH4HCO3 as
described previously (48).
In Situ Hybridization—Brains were quickly removed from
P7, P14, P21, and 7-week-old ddYmice and frozen in powdered
dry ice. Consecutive brain sections were cut at a thickness of 16
m with a cryostat (Leica Microsystems, Tokyo, Japan), thaw-
mounted onto 3-aminopropyltriethoxysilane-precoated glass
slides, and stored at 80 °C prior to use.
The pGEM-T Easy Vector containing a cDNA fragment
(2.0 kbp) of mouse GalNAc4S-6ST (UniGene Cluster Mm.
213582) was linearized with a restriction enzyme, NcoI or SalI,
for synthesis of antisense or sense RNA probes, respectively.
After enzymatic digestion, each digest was treated with a mix-
ture of phenol/chloroform/isoamyl alcohol (25:24:1) and puri-
fied by ethanol precipitation. 35S-Labeled riboprobes were
transcribed using a MAXIscriptTM T7 kit (Ambion, Austin,
TX) with 5--[35S]thiotriphosphate (30 TBq/mmol) (GE
Healthcare Bio-Sciences). Before being loaded on the slides, the
radiolabeled probes were mixed individually into a hybridiza-
tion buffer (50% (v/v) formamide, 10% (v/v) dextran sulfate,
2.5 Denhardt’s solution, 4 saline-sodium citrate (SSC), 5
mMEDTA, pH8.0, 0.5mg/ml tRNA frombrewers’ yeast (Roche
Applied Science), and 20 mM dithiothreitol) at a concentration
of 107 cpm/ml. In situ hybridization was performed as
described previously (49). Briefly, the brain sections were fixed
in 4% (v/v) formaldehyde in PBS at room temperature for 15
min. This was followed by digestion with proteinase K (2
mg/ml) at 37 °C for 10 min, acetylation in 0.25% (v/v) acetic
anhydride in 0.1 M triethanolamine at room temperature for 10
min, and dehydration through graded concentrations of etha-
nol. After drying, the tissue sections were pretreated with the
hybridization buffer without 10% (w/v) dextran sulfate at 55 °C
for 1 h and then with the hybridization buffer containing the
RNA probe prepared as above and incubated in a moisture
chamber at 55 °C for 18 h. The sections were then rinsed twice
in 2 SSC containing 10 mM 2-mercaptoethanol at room tem-
perature for 5 min; digested with RNase A (50 g/ml) at 37 °C
for 30 min; rinsed twice in 50% formamide, 2 SSC, 10 mM
2-mercaptoethanol at 55 °C for 30 min and subsequently in 2
SSC, 10 mM 2-mercaptoethanol at room temperature for 10
min; and dehydrated through graded concentrations of etha-
nol. The processed sections were exposed to x-ray films (Bio
Max MR; Eastman Kodak Co.) for 1 week for signal detection.
Immunohistochemistry—Immunostaining was done as
described previously (27). Briefly, cryosections (18m thick) of
mouse brain were fixed with acetone/methanol (1:1) and rehy-
drated with distilled water. The sections were then treated
sequentially with the following solutions: 1) 2.5% hydrogen per-
oxidase in PBS (10 mM, pH 7.4) for 30 min; 2) 1% BSA, 4%
normal horse serum inPBS for 60min; 3) primary phage display
antibody in 1% BSA, PBS (diluted 25-fold) overnight at 4 °C; 4)
anti-VSV tag mouse monoclonal IgG antibody, P5D4, in 1%
BSA, PBS (1,000-fold) for 60 min; 5) anti-mouse IgG biotiny-
lated antibody in 1% BSA, PBS (200-fold) for 60 min; 6) Vec-
tastain ABC solution in PBS (200-fold) for 60 min; 7) 0.06%
diaminobenzidine in PBS for 10 min; 8) 0.06% diaminobenzi-
dine, 0.01% hydrogen peroxide in PBS for 5 min. Finally, sec-
tions were fixed with a series of ethanol solutions and xylene
and then mounted with a xylene-based mounting medium. To
confirm the specificity of staining with the antibody, brain sec-
tions were treated with chondroitinase ABC protease-free (5
mIU/section) to remove CS and DS. To confirm the minimal
size for GD3G7, 1 nmol of the CS-E octa- or decasaccharide
fraction was preincubated with the primary antibody at 37 °C
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for 60 min before being added to the sections. In this case,
polyester wax sections were used as follows. Brains were fixed
overnight in a 3.7% formaldehyde solution and then dehydrated
through several changes of ice-cold 70%, 90%, and absolute eth-
anol for 15 min at room temperature. Subsequently, brains
were placed in 50% (v/v) polyesterwax in absolute ethanol over-
night at 37 °C followed by 90% polyester wax in absolute etha-
nol at 37 °C overnight. Brains were embedded in a 90% wax
solution, and the blockswere cut serially at 5mwith a cryostat
andweremounted onto glass slides. The slides were dried over-
night at 4 °C and then processed for immunostaining as
described above.
Cell Culture—Hippocampal cells were cultured using E16.5
mouse brains as described previously (16, 50). The hippocampi
were obtained by microdissection and dissociated with a brief
trypsin treatment. Dissociated cells were suspended in Eagle’s
modified essential medium containing an N2 supplement,
seeded on poly-DL-ornithine-coated coverslips, and cultured at
37 °C in a humidified atmosphere containing 5% CO2.
Neurite GrowthAssay—Neurite growth of hippocampal neu-
rons from E16.5 mouse brains was assayed as described previ-
ously (16, 50). Briefly, plastic coverslips (10  10 mm) were
treated with 1.5 g/ml of poly-DL-ornithine in 0.1 M borate
buffer, pH 8.2, for 2 h at room temperature and then further
coated with CS-E or laminin at a dose of 2 or 10 g/cm2 per
coverslip, respectively, in PBS at 4 °C overnight, washed with
PBS three times, and incubated with the antibody GD3G7 (10
and 100 g/ml). After 2 h of incubation at room temperature,
the coverslips were washed with PBS three times and then
seeded with hippocampal cells at 10,000 cells/cm2. An irrele-
vant scFv antibody, MPB49V (100 g/ml), without reactivity
toward GAGs was run as a negative control.
After a 24-h culture, cells were fixedwith 4% (w/v) paraform-
aldehyde and then immunostained with anti-MAP2 and anti-
neurofilament antibodies. The antibodieswere detected using a
Vectastain ABC kit with 3,3-diaminobenzidine as a chroma-
gen as described above. Neurite outgrowth was evaluated by
determining the mean length of the longest neurite per cell.
One hundred clearly isolated cells with at least one neurite lon-
ger than the cell bodywere chosen at randomper coverslip. The
results were expressed as the mean  S.E., and the significance
of differences between means was evaluated with Student’s t
test.
RESULTS
Evaluation of the Specificity of Antibody GD3G7 by ELISA—
The reactivity ofGD3G7 toward variousGAGpreparationswas
tested using ELISA, in which biotinylated GAGs were individ-
ually immobilized onto streptavidin-coated plates. GD3G7 spe-
cifically reactedwithCS-E, CS-H (oversulfatedDS fromhagfish
notochord, which contains iE as the predominant disaccharide
unit), and also with SS-DS (DS from shark skin, which contains
an appreciable proportion of E and iE units) and not with any
other GAGs tested, including CS-A, CS-B, CS-C, CS-D, and
heparin (Fig. 1). It should be emphasized that GD3G7 could
recognize both E (GlcUA-GalNAc(4S,6S)) and iE (IdoUA-
GalNAc(4S,6S)) units. To further investigate the specificity of
GD3G7 toward iE, an inhibitory ELISA was performed, in
which CS-B treated for enzymatic sulfation with or without
GalNAc4S-6ST was used as the inhibitor.
Human GalNAc4S-6ST transfers sulfate from PAPS to the
C-6 hydroxyl group of the GalNAc-4-O-sulfate residues of
CS-A and DS to form GlcUA-GalNAc(4S,6S) and/or IdoUA-
GalNAc(4S,6S) units (38). To facilitate the functional analysis
of GalNAc4S-6ST, the activity of a zebrafish counterpart was
assayed using CS-B as the acceptor and PAPS as the donor
substrate. To identify the reaction products, first gel filtration
was conducted using a Sephadex G-25 (superfine) column, and
then an aliquot of the flow-through fraction was digested
exhaustively with chondroitinase ABC, chondroitinase AC-I,
or chondroitinase B. It should be noted that the sulfation of
GalNAc residues flanking a target IdoUA residue is essential for
the action of chondroitinase B (46), although chondroitinase
AC-I reactions are little influenced by the sulfation pattern of
neighboring sugar residues. One half of each digest was ana-
lyzed by gel filtration on a SuperdexTM peptide column (Fig. 2,
A–C), and the other half of each digest was analyzed by anion
exchangeHPLC on an amine-bound silica PA-03 column using
a linearNaH2PO4 gradient from 16 to 530mMover a 1-h period
(Fig. 2, D–F).
The gel filtration chromatograms revealed that the 35S-la-
beled products after digestion with chondroitinase ABC or B
eluted at the position corresponding to disaccharides (Fig. 2, A
and C), whereas no detectable disaccharide products were
eluted after digestion with chondroitinase AC-I (Fig. 2B). The
integrated radioactivity of the disaccharide peak observed on
gel filtration was well consistent with that of Di-diSE (E)
FIGURE 1. Characterization of the substrate specificity of the single chain
variable fragment antibody GD3G7. The reactivity of the antibody GD3G7
with various GAG species was analyzed by ELISA, in which authentic commer-
cial GAGs (CS-A, CS-B, CS-C, CS-D, CS-E, and heparin (Hep)) and the DS prepa-
rations from hagfish notochord (CS-H) and shark skin (SS-DS) were included.
Biotinylated GAGs (2 g each) were individually immobilized to wells of a
streptavidin-coated plastic plate, and processed for incubation with the pri-
mary antibody GD3G7 (diluted 10-fold). Bound antibodies were visualized by
subsequent incubation with mouse anti-VSV antibody P5D4 followed by alka-
line phosphatase-linked goat anti-mouse Ig (G  M) (diluted 5,000-fold).
Enzymatic activity was measured using p-nitrophenylphosphate as a sub-
strate at 415 nm. Negative controls received no primary antibody. Bars,
mean  S.D. (n  3).
Single Chain Antibody GD3G7 Recognizing CS-E and DS-E














detected by anion exchange HPLC analysis using the other half
of each digest, demonstrating that the majority of 35S-labeled
Di-diSE was released from the -IdoUA-GalNAc(4S,6S)-
IdoUA- sequence by digestion with chondroitinase ABC and
chondroitinase B (Fig. 2, D and F) and not from the -GlcUA-
GalNAc(4S,6S)-GlcUA- sequence, since no products were
detected after treatment with chondroitinase AC-I (Fig. 2E).
These results suggest that when CS-B was used as the acceptor
molecule, GalNAc4S-6ST catalyzed the sulfation of
GalNAc(4S) residues adjacent to IdoUA rather than GlcUA,
thereby generating iE disaccharide units. Under the same assay
condition, a soluble form of mouse GalNAc4S-6ST also cata-
lyzed the formation of iE units, although only a relatively small
proportion (29%) of the total radioactivity was detected at the
position ofE for the chondroitinase B digest (data not shown).
Hence, to produce iE units in vitro, the soluble formof zebrafish
GalNAc4S-6ST was used for enzymatic synthesis of iE unit-
containing polysaccharides as described below.
Evaluation of Specificity of GD3G7 toward iE—Zebrafish
GalNAc4S-6ST preferentially transferred sulfate to the 6-O-
position of GalNAc(4S) residues adjacent to IdoUA residues in
CS-B, which contains 95% IdoUA-GalNAc(4S), thereby gen-
erating iE (IdoUA-GalNAc(4S,6S)) disaccharide units. To fur-
ther evaluate the specificity of GD3G7 toward iE, we assessed
the ability of CS-B treated with or without GalNAc4S-6ST to
inhibit the binding of GD3G7 to immobilized CS-E. As shown
in Fig. 3, CS-B treated with GalNAc4S-6ST showed significant
inhibition for the binding of GD3G7 toCS-E, whereas CS-B not
treated with GalNAc4S-6ST showed no inhibition against the
binding of GD3G7 to CS-E, suggesting that GD3G7 specifically
reacted with iE. Inhibitory activity was also exhibited by CS-H
but not CS-D. The current data thus support the conclusion
that GD3G7 recognizes both E and iE disaccharide units.
Expression of GalNAc-4-sulfate 6-O-Sulfotransferase in the
Mouse Brain during Postnatal Development—CS/DS chains
regulate the development of the central nervous system and
play various roles as neuritogenic molecules. It has been previ-
ously demonstrated that IdoUA-containing structures in
CS/DS hybrid chains from embryonic pig brain are essential for
neuritogenic and growth factor-binding activity (51). Hence, to
gain insights into the distribution of CS/DS hybrid chains con-
taining E/iE units in the mouse brain during postnatal develop-
ment, expression of the mouse GalNAc4S-6ST was examined
by in situ hybridization with the 35S-labeled antisense probe.
Fig. 4 presents film autoradiograms of sagittal sections from
the brains of P7 (Fig. 4A), P14 (Fig. 4B), and P21 (Fig. 4C) mice.
TheGalNAc4S-6ST transcript was observed inmany regions of
FIGURE 2. Anion exchange HPLC and gel filtration chromatographic anal-
yses of the reaction products prepared using zebrafish GalNAc4S-6ST as
an enzyme source and nitrous acid-treated CS-B as the sulfate acceptor.
An aliquot of 35S-labeled CS-B produced by zebrafish GalNAc4S-6ST was
digested with chondroitinase ABC (A and D), AC-I (B and E), or B (C and F).
One-half of each digest was analyzed by gel filtration on a Superdex peptide
column (A–C). The other half was analyzed by anion exchange HPLC on an
amine-bound silica PA-03 column using a linear NaH2PO4 gradient, as indi-
cated by dashed lines, over a 60-min period (D–F). The vertical lines indicate
the elution positions of standard even-numbered oligosaccharides derived
from porcine skin DS (34). A–C, bar 1, hexasaccharides; bar 2, tetrasaccharides;
bar 3, disaccharides. D–F, the numbered arrows indicate the elution positions
of the authentic unsaturated disaccharides. Arrow 1, Di-0S (O); arrow 2,
Di-6S (C); arrow 3, Di-4S (A); arrow 4, Di-diSD (D); arrow 5, Di-diSE
(E); arrow 6, Di-triS (T).
FIGURE 3. Reactivity of antibody GD3G7 toward CS-B treated with GalNAc
4S-6ST. CS-B treated with zebrafish GalNAc4S-6ST was used as an inhibitor of
the binding of GD3G7 to immobilized CS-E. Each GAG at 0.1 g (white bars),
0.5 g (gray bars), and 1.0 g (black bars) was tested by performing an inhib-
itory ELISA. GalNAc4S-6ST transferred sulfate to the 6-O-position of GalNAc4S
residues adjacent to IdoUA in CS-B and eventually generated iE units. Note
that GalNAc4S-6ST-treated CS-B and also CS-H inhibited the binding of
GD3G7 to CS-E, whereas native CS-B or CS-D did not bind GD3G7. Values were
obtained from the average of two separate experiments.
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the developing brain including the olfactory bulb, cerebral cor-
tex, hippocampus, cerebellum, and striatum. In a negative con-
trol experiment with the 35S-labeled sense probe, no labeling
was observed in any region of brain sections of a P21 mouse
(Fig. 4E) or in a P7 or P14 mouse (data not shown), confirming
the specific hybridization of the antisense probe. The expres-
sion of this gene was confined to the cerebellum in P7 mice,
with strong expression observed in the external granule cell
layer (Fig. 4A). The cerebellar expression switched from the
external granule cell layer to internal granule cell layer and
appeared to decrease slightly with development (Fig. 4, A–D),
probably reflecting the migration and/or maturation of granu-
lar cells. This gene expression suggests that CS/DS chains con-
taining E and/or iE units are relatively abundant in the cerebel-
lum of P7 mice and gradually decrease during postnatal
development. It is interesting to note that GalNAc4S-6STmes-
sage was also highly expressed in the dentate gyrus of hip-
pocampus and olfactory bulb (Fig. 4, A–D), where neurons
are continuously replaced throughout life (52), and in the
striatum (Fig. 4, A–D). The gene expression profile provides
insight into the possible involvement of the E/iE unit-con-
taining CS/DS chains in neurogenesis and in the organiza-
tion of the nigrostriatal system.
Immunohistochemical Detection and Distribution of GD3G7
Epitope in the Mouse Brain—To study the expression of the
unique GD3G7 epitope in the mouse brain, immunohisto-
chemical expression of P7 brain sections was performed using
the antibody GD3G7. Consecutive sagittal sections from P7
mouse brain were incubated with GD3G7, and the bound anti-
bodieswere detected by anti-VSV-tag P5D4 antibodies andbio-
tinylated anti-mouse IgG antibodies tagged with peroxidase
and visualized by 3,3-diaminobenzidine (the substrate for per-
oxidase). The staining pattern of the sagittal sections of P7mice
is shown in Fig. 5. GD3G7 specifically stained the P7 cerebel-
lum, hippocampus, and olfactory bulb. The staining was stron-
ger in the cerebellum, whereGD3G7 stainedmost intensely the
developingmolecular layer at its border with the external gran-
ular layer. During the neonatal development of the cerebellum,
the generation of granule cells occurs in the proliferative zone
of the external granular layer (53), where GalNAc4S-6ST was
strongly expressed (Fig. 4A). Granule cells start to exit the cell
cycle after birth, and as part of their differentiation program
they migrate internally, passing through the molecular layer
and Purkinje cells to form the inner granular layer (54). Since
the staining of the molecular layer was reduced in the P21 sec-
tions (data not shown), the staining of the molecular layer with
GD3G7 at P7 may be, in part, due to the close apposition of
internally migrating granule cells. In the hippocampus, the
GD3G7 reactivity was observed in the areas surrounding the
pyramidal cell layer of the CA1-CA3 fields and the granular cell
layer of the dentate gyrus. In the olfactory bulb, the GD3G7
epitope was expressed in the glomerular layer as well as the exter-
nal andplexiform layers.These stainingpatterns in thehippocam-
pus and olfactory bulb are indicative of a role for the epitope in
axon tract formation. The staining of
the brain was completely abolished
upon the treatment of the tissue sec-
tions with chondroitinase ABC,
confirming the specificity of the
staining. These results suggest that
CS-E is highly expressed in the cer-
ebellum and also in the hippocam-
pus and olfactory bulb of P7 mouse
brain.
Effects of GD3G7 on the Neurite
Outgrowth of Hippocampal Neu-
rons—CS-E promotes the out-
growth of neurites in rat E18 hip-
pocampal neurons. The antibody








FIGURE 4. In situ hybridization for GalNAc4S-6ST in the mouse brain dur-
ing postnatal development. Consecutive sagittal sections of the brain from
P7 (A), P14 (B), P21 (C and E) and 7-week-old (D) mice were hybridized with
35S-labeled antisense (A–D) or sense (E) cRNA probes for GalNAc4S-6ST and
exposed to an x-ray film for 1 week. No labeling was observed in the respec-
tive neighboring sections hybridized with the sense probe (E and data not
shown). The GalNAc4S-6ST transcript showed a widespread expression in the
developing brain except at P7, when strong expression was observed in the
external granule cell layer (arrowhead) in the cerebellum. The expression in
the granule cell layer switched to the internal region and appeared to
decrease slightly with development. Strong expression of GalNAc4S-6ST was
also observed in the olfactory bulb, hippocampus, cerebral cortex, and stria-
tum of the developing brain. OB, olfactory bulb; Cx, cerebral cortex; Hi, hip-
pocampus; Cb, cerebellum; St, striatum. Scale bar, 5 mm.
FIGURE 5. Immunohistochemical localization of GD3G7 epitope in mouse brain. Consecutive sagittal sec-
tions from P7 mouse brain were stained using the single chain variable fragment anti-CS antibody GD3G7 as
described under “Experimental Procedures.” Immunoreactivity to GD3G7 was observed in the P7 cerebellum,
hippocampus, and olfactory bulb. The staining completely disappeared upon treatment of the tissue sections
with chondroitinase ABC. Scale bars, 2 mm. OB, olfactory bulb; Cx, cerebral cortex; Hi, hippocampus; Cb,
cerebellum.
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structure embedded in CS-E. To investigate whether the
GD3G7 epitope in CS-E is involved in the process of neurite
outgrowth in hippocampal neurons, the antibody was added to
the culturemediumat two different concentrations (10 and 100
g/ml) 2 h prior to the seeding of the neuronal cells on the
substratum coated with CS-E. The antibody significantly sup-
pressed the growth of neurites in the neurons grown on the
substratum containing CS-E (Fig. 6, A and B). This observation
was confirmed by a statistical morphometric analysis, which
revealed that GD3G7markedly inhibited the formation of neu-
rites and decreased the total length of neurites per cell at a
concentration of 100 g/ml (Fig. 6C). However, GD3G7
showed no significant inhibition against the neurite outgrowth
induced by a laminin substrate (supplemental Fig. S1), suggest-
ing that the inhibition was specific to CS-E-stimulated neurite
outgrowth. Control scFv antibody (MPB49V, 100 g/ml)
showed no neutralizing activity either. These results demon-
strated that the epitope of GD3G7 is embedded in the neurite
outgrowth-promoting motif of CS-E.
Characterization of the Minimal Structure Required for Rec-
ognition by GD3G7—In view of the finding that the epitope of
GD3G7 in CS-E may be involved in the neurite outgrowth-
promoting activity, we characterized the minimal structure of
CS-E required for recognition by this antibody. Even-num-
bered CS-E oligosaccharide fractions, which were prepared by
partial digestion of CS-E from squid cartilage with sheep testi-
cular hyaluronidase (40), were used as inhibitors for the binding
ofGD3G7 to immobilizedCS-E. Fig. 7A shows that decasaccha-
rides and larger oligosaccharides exhibited inhibitory activity,
and the activity increased with molecular size, although the
FIGURE 6. Effect of a single chain variable fragment antibody GD3G7 on
the neurite growth of hippocampal neurons in culture. Antibody GD3G7
was added to the culture medium at two different concentrations (10 and 100
g/ml) 2 h prior to the seeding of hippocampal cells from E16.5 mice on a
substratum coated with CS-E. After a 24-h culture, the cells were immuno-
stained with anti-MAP2 and anti-neurofilament antibodies. Representative
images of the cell morphology obtained in the absence (A) or presence (B) of
100 g/ml GD3G7 are shown. C, effects of GD3G7 on neurite growth were
evaluated by measuring the total length of the neurites per cell. An irrelevant
scFv antibody MPB49V (100 g/ml) was run as a negative control. The values
represent the mean  S.D. of those obtained from two independent experi-
ments in triplicate. **, 0.001 	 p 	 0.01, significant difference from the values
obtained in the experiments without exogenous antibody. FIGURE 7. Determination of the minimum size of CS-E oligosaccharides
for the recognition by GD3G7. A, even-numbered oligosaccharide fractions
(0.5 g) derived from CS-E of squid cartilage were tested by ELISA as inhibitors
of the reactivity of GD3G7 with immobilized CS-E. Note that the decasaccha-
ride fraction was the smallest fraction to show significant inhibitory activity,
although the octasaccharide fraction seemed to react slightly with GD3G7
compared with the hexasaccharide fraction. B, different doses of CS-E octa-
and decasaccharide fractions (0, 0.5, 1, and 2 g) were tested by ELISA as an
inhibitor of the reactivity of GD3G7 with immobilized CS-E. Note that GD3G7
reacted preferentially with the decasaccharide fraction from CS-E. Values
were obtained from the average of two separate experiments.
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octasaccharide fraction seemed to react only slightly with
GD3G7 compared with the hexasaccharide fraction.
Next, to precisely determine the minimal structure of CS-E
recognized by GD3G7, varying doses of CS-E octa- and
decasaccharides were used as inhibitors against the binding of
GD3G7 to CS-E. Fig. 7B shows that GD3G7 reacted preferen-
tially with the decasaccharide fraction from CS-E but not at all
with the octasaccharide fraction. The degree of binding of
GD3G7to theCS-Edecasaccharide fraction increased inadose-
dependent manner, whereas there was no binding to the
octasaccharide fraction even at higher doses. These results
were consistent with the above finding that the decasaccharide
fraction derived from CS-E meets the critical minimal size
needed for recognition by GD3G7.
We sought to corroborate the
ELISA data by assessing the immu-
noreactivity of the antibody in brain
sections using CS-E oligosaccha-
rides as inhibitors. CS-E-derived
octa- and decasaccharide fractions
were used as inhibitors for the
immunohistochemical staining of
mouse brain sections from postna-
tal day 7. GD3G7 was incubated
with 1 nmol each of the CS-E octa-
and decasaccharide fractions at
room temperature for 1 h prior to
the incubation with the brain sec-
tions. The staining pattern of the
sagittal sections from the brain of P7
mice is shown in Fig. 8. Preincuba-
tion of GD3G7 with the CS-E decasaccharide prevented the
antibody from staining the sections, whereas immunostaining
in the cerebellum, hippocampus, and olfactory bulb was still
visible when the CS-E octasaccharide was used as an inhibitor.
The finding that theCS-E decasaccharide fractionwas themost
efficient inhibitor of GD3G7 indicates that a CS-E-derived
decasaccharide fraction is the minimal structural requirement
for the binding of GD3G7.
To further characterize the epitope structure ofGD3G7, four
structurally defined decasaccharide fractions and one octasac-
charide fraction derived from CS-E were used in an inhibitory
ELISA experiment for the binding of GD3G7 to CS-E. It was
found that all four decasaccharide fractions inhibited the bind-
ing of GD3G7 to immobilized CS-E, but the octasaccharide
fraction did not (Fig. 9), which is basically in agreementwith the
size-dependent reactivities observed in Fig. 7B. The structure of
the oligosaccharides is summarized in Table 1. GD3G7 reacted
preferentially with all of the structurally defined decasacchar-
ides, whereas the octasaccharide with four E units was not
bound by this antibody. The observed binding preference sug-
gests that this antibody can recognize decasaccharides with a
minimum of three consecutive E units.
DISCUSSION
In this study, the characteristic spatiotemporal distribution
of CS-E/DS-E hybrid chains in the postnatal mouse brain was
examined in detail using an antibody, GD3G7, produced by the
phage display technique. This antibody reacted specifically
with CS-E, but also with CS-H, which consists of characteristic
iE units (29, 30, 55), and with SS-DS, where E (or iE) units
account for 10% of all the disaccharide (17), as evaluated by
ELISA, suggesting that the essential recognition unit is a
GalNAc(4S,6S) residue, irrespective of whether GlcUA or
IdoUA is attached to it. CS-H is derived from the hagfish noto-
chord (29), and the corresponding mammalian tissue produces
the soluble Sonic Hedgehog protein, implicated in the genera-
tion of ventral neurons and the differentiation of motor neu-
rons (56). CS-H is structurally similar to CS-E but contains
IdoUA instead of GlcUA as a major uronic acid and is regarded
as an oversulfated DS (26). In situ hybridization for GalNAc4S-
6ST, which is involved in the biosynthesis of CS-E/DS-E,
FIGURE 8. Effect of CS-E oligosaccharides on the immunohistochemical staining of GD3G7 epitope in
mouse brain. CS-E deca- and octasaccharides (1 nmol) were tested as inhibitors of the staining of GD3G7 in P7
mouse brain. Note that preincubation of GD3G7 with decasaccharides abolished the staining of the mouse
brain sections, whereas the staining was still observed after using octasaccharides as inhibitors.
FIGURE 9. Reactivity of structurally defined CS-E octa- and decasacchar-
ides with GD3G7. Four structurally defined decasaccharide fractions and
one octasaccharide fraction prepared from CS-E were used as inhibitors of the
reactivity of GD3G7 with immobilized CS-E. 0.01, 0.05, and 0.1 nmol of each
decasaccharide fraction and 0.1 nmol of octasaccharide fraction were tested.
Note that all four decasaccharide fractions but not the octasaccharide
showed inhibitory activity. The values represent the mean  S.D. of those
obtained from two independent experiments.
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showed that CS-E/DS-E hybrid chains are more concentrated
in the cerebellum, providing insight into the importance of
these hybrid chains during the brain’s development.
GalNAc4S-6ST transfers sulfate from PAPS to position 6 of
GalNAc(4S) in CS and DS (38). In vitro synthesis of DS-E from
CS-B was carried out using purified GalNAc4S-6ST, which
preferentially generated IdoUA1–3GalNAc(4S,6S). Interest-
ingly, the product inhibited the binding of GD3G7 to immobi-
lized CS-E, indicating that the antibody GD3G7 recognized an
iE-enriched region in CS-B. Thus, GD3G7 recognizes both E
and iE units and will be a useful tool to study the distribution of
E- and iE-containing CS/DS structures.
The importance of the differential expression of sulfotrans-
ferases has not been fully evaluated. Kitagawa et al. (13) dem-
onstrated that the sulfation profile of CS chains and the ratio of
chondroitin 4-O-sulfotransferase and chondroitin 6-O-sulfo-
transferase activities forming the specific sulfation profile
changed markedly with development in the chick embryonic
brain, and these alterations were precisely coordinated. Here,
we have shown for the first time the distribution ofGalNAc4S-
6ST in the developing brain. The strong expression of
GalNAc4S-6ST was confined in the external granule cell layer
in the cerebellum (Fig. 4A) of P7 mouse brain. Its restricted
expression switched to the internal granule cell layer and prob-
ably the Purkinje cell layer and decreased slightly with develop-
ment, demonstrating that E/iE-containing CS/DS chains play
critical roles during brain development. GalNAc4S-6ST was
also found to be strongly expressed in the olfactory bulb, hip-
pocampus, cerebral cortex, and striatum of the developing
brain, suggesting the involvement of E/iE-containing CS/DS
chains in neurogenesis, axon guidance, and/or neuronal sur-
vival in these regions. Recently, it has been demonstrated that
appican, the CS-PG form of the Alzheimer’s amyloid precursor
protein, produced by glioma cells, contains 14.3% CS-E (28).
The CS chain in appican is responsible for the adhesion of neu-
ral cells and for promoting the outgrowth of neurites in primary
rat hippocampal cultures, because the core of the Alzheimer
amyloid precursor protein is less potent in promoting adhesion
and neurite outgrowth than is appican PG (57, 58). The pres-
ence of E units in appican PG may explain the neurotrophic
activities of appican. The hypothesis that oversulfated disac-
charides are mainly responsible for the neurotrophic activities
shown by specific CS-PGs is based on the pioneering observa-
tions that oversulfated squid CS-E as well as shark CS-D pro-
motes neurite outgrowth in cultures of primary rat hippocam-
pal neurons (15, 59). By contrast, CS-PGs lacking oversulfated
units either fail to promote neurite outgrowth or show inhibi-
tory activity (60). Our observation that the postnatal brain con-
tains oversulfated E units supports this hypothesis and suggests
that CS-E/DS-E may function in the brain to promote neurite
outgrowth. Recently, it has been demonstrated that CS-E can
bind various growth factors (61), suggesting that its neuroregu-
latory activities are exerted through signal transduction medi-
ated by various growth factors. In fact, it was recently demon-
strated that CS/DS chains derived from embryonic pig brain
recruited endogenous PTN to promote neuritogenesis in a hip-
pocampal cell culture system (42), although the core proteins of
the CS/DS chains have not been identified. Previously, a trans-
membrane PG, syndecan-1 from mouse mammary gland epi-
thelial cells, was demonstrated to bear E-containing CS chains
(62), although it is unknown whether syndecan-1, expressed in
the rat central nervous system, which binds MK and PTN (63),
contains CS-E.
The E unit has been demonstrated in appreciable propor-
tions in CS chains from bovine brain (24) and chick brain,
where it exhibits a developmentally regulated expression (13).
Interestingly, the antibodyGD3G7 stained restricted regions in
the P7 mouse brain, indicating the expression of CS-E/DS-E-
containing structures in the mammalian brain. However, it
remains to be determined whether the GD3G7 epitope in the
mouse brain is embedded in the DS domains that contain iE
units. Oversulfated disaccharides, such as D/iD, B/iB, and E/iE,
have been implicated in the development of the brain (6, 16, 18).
Recently, Bao et al. (27) demonstrated the presence of func-
tional iD-containing domains in the developing mouse brain
using a monoclonal antibody, 2A12, against the DS from
ascidian. Maeda et al. (12) have reported the systematic
immunohistochemical localization of several CS epitopes,
including CS-56 and MO-225 epitopes in the developing
postnatal mouse brain. The CS-56 epitope is highly
expressed in the cerebral cortex early in the postnatal period,
and its expression is markedly decreased 3 weeks after birth
(12). In contrast, the expression of the MO-225 epitope is
weak in the cerebral cortex but stronger in other regions,
including the cerebellum, during the developing stages.
MO-225 reactivity in the cerebellum reaches a peak at post-
natal day 14 and decreases thereafter (12). The original study
by Yamagata et al. (64) showed the reactivity ofMO-225 with
the tetrasaccharides A-D and E-D. Recently, Ito et al. (65)
have shown that MO-225 could strongly react with octasac-
charide and larger oligosaccharide fractions derived from
CS-D of shark cartilage, and Deepa et al. (41) showed that
MO-225 reacted with a decasaccharide sequence rich in E
units, prepared from squid cartilage CS-E.
CS-E promoted the outgrowth of axon-like neurities toward
neurons in a hippocampal cell culture (15). GD3G7 antibody
inhibited the neuritogenic activity mediated by CS-E, suggest-
TABLE 1
Reactivity of the CS-E oligosaccharide fractions to the single chain
antibody GD3G7
Fractionsa Recognition by GD3G7b Component structuresc
VIIIs  E-E-E-E-E (80%)
E-E-E-E-A (20%)




VIIIq  E-E-E-E-A (96%)
E-E-E-E-C (4%)
VIIIm  C-E-E-E-A (35%)
E-E-E-A-A (58%)





bPlus () and minus () indicate positive and negative inhibitory activity, respec-
tively, against the binding ofGD3G7 to immobilizedCS-E in ELISA as described in
the legend to Fig. 9.
cE, A, and C represent GlcUA-GalNAc(4S,6S), GlcUA-GalNAc(4S), and GlcUA-
GalNAc(6S), respectively.
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ing that the functional domain for the neuritogenic activity of
the CS-E chains also includes the GD3G7 epitope. Ueoka et al.
(26) have shown the presence of CS-E in E18 rat brains and also
that the oversulfated E motif appears to be involved in the neu-
roregulatory activities of MK. It remains to be investigated,
however, which CS-PGs in the brain contain the E motif.
Despite the identification of soluble CS-PGs, such as brevican
(66) andneurocan (67), aswell as transmembraneCS-PGs, such
as NG2 (68), PTP, and neuroglycan C (69), the CS chains
attached to the core proteins have not been rigorously investi-
gated.Maurel et al. (70) have shown that phosphacan, an extra-
cellular variant of PTP, a receptor-type protein-tyrosine phos-
phatase that is abundantly expressed in the brain, binds PTN,
which binds to the same gene family as MK, and the binding of
PTN to phosphacan/PTP was dependent on the CS portion of
this proteoglycan, and various CS preparations competitively
inhibited this binding (71, 72). Notably, squid cartilage CS-E,
which has a high proportion of E units, inhibited the binding
very efficiently, suggesting that oversulfated CS structures play
important roles in the binding of phosphacan/PTP to PTN
(71, 72). It is possible that PTP and/or phosphacan bear CS
chains with distinctive sulfation profiles during different devel-
opmental stages. PTP/phosphacan-PTN signaling is involved
in the neurite extension, neuronalmigration, gliomamigration,
and morphogenesis of Purkinje cells (for reviews, see Refs.
71–75). Deepa et al. (61) have shown that PTN andMK interact
with CS-E. In view of these reports, the possibility cannot be
excluded that specific oligosaccharide sequences in the brain
containing E/iE units are responsible for the high affinity bind-
ing of MK and PTN to PTP and thereby mediating the neuri-
togenesis of cerebellar neurons.
We also demonstrated that a CS-E decasaccharide fraction
was the smallest oligosaccharide fraction to inhibit the binding
ofGD3G7 toCS-E, and larger oligosaccharide fractions showed
stronger inhibition. The CS-E decasaccharide fraction also had
an inhibitory effect on the reactivity of GD3G7 with sections of
mouse brain, confirming the notion that the decasaccharide
was the minimal size required for the binding of GD3G7. The
reactivity of GD3G7 with structurally defined octa- and
decasaccharides suggests that a decasaccharide with three con-
secutive E units may be a possible epitope structure for GD3G7
but not an octasaccharide with four consecutive E units. Thus,
it was concluded that not only the E units but also size is impor-
tant for recognition by this antibody. Also, the possibility can-
not be excluded that the GD3G7 epitope in the brain may be a
decasaccharide with core E and or iE units or a mixture of E/iE
units scattered along the functional domain. The isolation of
GD3G7-reactive structures from brain-derived CS/DS chains
will help clarify the structures of this unique epitope.
The results altogether demonstrate that CS-E/DS-E
expressed in the brain plays vital roles during brain develop-
ment. The human scFv antibody described here can be used as
a tool to visualize structural diversity in CS as illustrated for
other antibodies (76, 77). Since the cDNA of the single chain
antibody is available, antibodies can be produced and purified
in large quantities. It will be interesting to identify the PGs
carrying such a unique E/iE-containing GD3G7 epitope, which
would provide valuable information on the functions ofCS-PGs
during the development of the central nervous system.
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